AXSM has been the subject of a number of other reports. Cantor Fitzgerald set a $13.00 target price on shares of Axsome Therapeutics and gave the stock a buy rating in a report on Wednesday, August 10th. Zacks Investment Research raised shares of Axsome Therapeutics from a sell rating to a hold rating in a research note on Wednesday, July 27th.
Shares of Axsome Therapeutics (NASDAQ:AXSM) traded down 0.24% during mid-day trading on Monday, reaching $8.25. The company had a trading volume of 15,443 shares. The company’s 50-day moving average is $7.47 and its 200 day moving average is $8.40. The stock’s market capitalization is $157.98 million. Axsome Therapeutics has a 52-week low of $5.37 and a 52-week high of $15.74.
Institutional investors have recently bought and sold shares of the company. Teachers Advisors Inc. purchased a new position in Axsome Therapeutics during the second quarter worth approximately $128,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Axsome Therapeutics during the second quarter worth about $134,000. Bank of New York Mellon Corp bought a new stake in shares of Axsome Therapeutics during the second quarter worth about $161,000. California State Teachers Retirement System bought a new stake in shares of Axsome Therapeutics during the second quarter worth about $176,000. Finally, BlackRock Investment Management LLC raised its stake in shares of Axsome Therapeutics by 3,828.0% in the second quarter. BlackRock Investment Management LLC now owns 38,062 shares of the company’s stock worth $287,000 after buying an additional 37,093 shares during the period. 30.30% of the stock is owned by hedge funds and other institutional investors.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.